Seattle Genetics (SGEN) Tops Q4 EPS by 2c, Beats on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Seattle Genetics (SGEN) PT Raised to $77 at H.C. Wainwright
February 7, 2018 7:24 AM ESTH.C. Wainwright raised its price target on Seattle Genetics (NASDAQ: SGEN) to $77.00 (from $75.00) while maintaining a Buy rating.
Analyst Andrew Fein commented, "Beyond ADCETRISs continuous label expansion/revenue growth and the companys ADC platform milestone generation, we see the solid tumor pipeline as the most interesting value driver with three late-stage programs that could expand SGENs footprint beyond hematology. The recent acquisition of Cascadian Therapeutics (CASC; not rated) and its HER2+ breast cancer... More
Seattle Genetics (SGEN) PT Raised to $60 at SunTrust Robinson Humphrey
February 7, 2018 7:10 AM ESTSunTrust Robinson Humphrey raised its price target on Seattle Genetics (NASDAQ: SGEN) to $60.00 (from $52.00) while maintaining a Hold rating.
Analyst Suneja Yatin commented, "SGEN reported a slight (+3%) beat in Adcetris 4Q sales, while LPS also topped Street (-$0.41 vs. -$0.45E) on... More
